# US 4,399,132 A · 7-Beta-[alpha-syn-methoxyimino-alpha-(2-aminothiazol-4-yl)-aceta mido]-3-[(1,2,3-thiadiazol-5-ylthio)methyl]-3-cephem-4-carboxylic acid and C.sub.1 -C.sub.6 alkyl derivatives thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 4,399,132 A
- Document ID: US4399132A
- Status: Granted
- Kind: A
- Application number: 06/281,438
- Filed: 1981-07-08
- Granted: 1983-08-16
- Earliest claimed: 1980-08-11
- Assignees: American Cyanamid Company
- Inventors: William V. Curran; Adma S. Ross
- Web page: https://patentgrep.com/patent/US4399132A

## CPC

- C07D 501/36: Methylene radicals, substituted by sulfur atoms
- A61P 31/04: Antibacterial agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

7-Beta-[alpha-syn-methoxyimino-alpha-(2-aminothiazol-4-yl)acetamido]-3-[(1, 2,3-thiadiazol-5-ylthio)methyl]-3-cephem-4-carboxylic acid and C.sub.1 -C.sub.6 alkyl derivatives thereof, useful as antibacterial agents.

## Claims

### Claim 1

A compound selected from those of the formula: ##STR6## wherein R is selected from the group consisting of hydrogen and R.sub.1, wherein R.sub.1 is C.sub.1 -C.sub.6 alkyl; and the pharmaceutically acceptable nontoxic cation salts thereof.

### Claim 2 (depends on 1, 7)

The compound of claim 1, 7.beta.-[.alpha.-syn-methoxyimino-.alpha.-(2-aminothiazol-4-yl)acetamido]- 3-[(1,2,3-thiadiazol-5-ylthio)methyl]-3-cephem-4-carboxylic acid.

### Claim 3 (depends on 1, 7)

The compound of claim 1, 7.beta.-[.alpha.-syn-methoxyimino-.alpha.-(2-aminothiazol-4-yl)acetamido]- 3-[(1,2,3-thiadiazol-4-methyl-5-ylthio)methyl]-3-cephem-4-carboxylic acid.

### Claim 4

A method for treating bacterial infections in warm-blooded animals which comprises administering to said animals an effective amount of a compound selected from those of the formula: ##STR7## wherein R is selected from the group consisting of hydrogen and R.sub.1, wherein R.sub.1 is C.sub.1 -C.sub.6 alkyl; and the pharmaceutically acceptable nontoxic cationic salts thereof.

### Claim 5 (depends on 4)

The method in accordance with claim 4, wherein the compound is 7.beta.-[.alpha.-syn-methoxyimino-.alpha.-(2-aminothiazol-4-yl)acetamido]- 3-[(1,2,3-thiadiazol-5-ylthio)methyl]-3-cephem-4-carboxylic acid.

### Claim 6 (depends on 4)

The method in accordance with claim 4, wherein the compound is 7.beta.-[.alpha.-syn-methoxyimino-.alpha.-(2-aminothiazol-4-yl)acetamido]- 3-[(1,2,3-thiadiazol-4-methyl-5-ylthio)methyl]-3-cephem-4-carboxylic acid.

### Claim 7

A composition of matter which comprises an effective amount of a compound of the formula: ##STR8## wherein R is selected from the group consisting of hydrogen and R.sub.1 wherein R.sub.1 and C.sub.1 -C.sub.6 alkyl, and the pharmaceutically acceptable nontoxic cationic salts thereof, in association with a pharmaceutically acceptable carrier.

### Claim 8 (depends on 7)

The composition of matter in accordance with claim 7, wherein the compound is 7.beta.-[.alpha.-syn-methoxyimino-.alpha.(2-aminothiazol-4-yl)acetamido]-3 -[(1,2,3-thiadiazol-5-ylthio)methyl]-3-cephem-4-carboxylic acid.

### Claim 9 (depends on 7)

The composition of matter in accordance with claim 7, wherein the compound is 7.beta.-[.alpha.-syn-methoxyimino-.alpha.-2-aminothiazol-4-yl)acetamido]-3 -[(1,2,3-thiadiazol-4-methyl-5-ylthio)methyl]-3-cephem-4-carboxylic acid.